Cav 3.2 inhibitor 2 

Cav 3.2 inhibitor 2 is a Ca_v3.2 T-type Ca²⁺ channels inhibitor with an IC₅₀ of 0.09339 μM under -80mV holding potential. Cav 3.2 inhibitor 2 potently suppresses T-channel-dependent somatic and visceral pain in mice. Cav 3.2 inhibitor 2 can be used for the research of intractable pain^[1].

IC50: 0.09339 μM (-80mV Ca_v3.2), 1.109 μM (-110mV Ca_v3.2), 0.2167 μM (Ca_v3.1)^[1]

Cav 3.2 inhibitor 2 (0.3 μM) shows a produced inhibition of Ca_v3.2 comparable to that of pimozide^[1].
Cav 3.2 inhibitor 2 (1 and 10 μM; 90 min) shows a binding affinity to D2 receptor significantly less than pimozide^[1].
Cav 3.2 inhibitor 2 (0.01-10 μM) inhibits T channels isoforms with IC₅₀s of 0.09339, 1.109 and 0.2167 μM for -80mV Ca_v3.2, -110mV Ca_v3.2 and Ca_v3.1, respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cav 3.2 inhibitor 2 (1-10 mg/kg; i.p. 30 min before i.pl. Na₂S) affects the Na₂S-induced pain in vivo^[1].
Cav 3.2 inhibitor 2 (10 mg/kg; i.p. 7 days after oxaliplatin treatment) affects oxaliplatin-induced allodynia in vivo^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

517.65

C₃₂H₃₇F₂N₃O

2878598-92-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kasanami Y, et al. Discovery of pimozide derivatives as novel T-type calcium channel inhibitors with little binding affinity to dopamine D2 receptors for treatment of somatic and visceral pain. Eur J Med Chem. 2022 Aug 27;243:114716.  [Content Brief]